Código QR

Open-label phase I clinical trial of Ad5-EBOV in Africans in China

Background: To determine the safety and immunogenicity of a novel recombinant adenovirus type 5 vector based Ebola virus disease vaccine (Ad5-EBOV) in Africans in China. Methods: A phase 1, dose-escalation, open-label trial was conducted. 61 healthy Africans were sequentially enrolled, with 31 parti...

Descripción completa

Guardado en:
Autores principales: Lihua Wu, Zhe Zhang, Hainv Gao, Yuhua Li, Lihua Hou, Hangping Yao, Shipo Wu, Jian Liu, Ling Wang, You Zhai, Huilin Ou, Meihua Lin, Xiaoxin Wu, Jingjing Liu, Guanjing Lang, Qian Xin, Guolan Wu, Li Luo, Pei Liu, Jianzhong Shentu, Nanping Wu, Jifang Sheng, Yunqing Qiu, Wei Chen, Lanjuan Li
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis Group 2017-09-01
Colección:Human Vaccines & Immunotherapeutics
Materias:
ad5-ebov
gp antibody
immunogenicity
safety
t-cell response
Acceso en línea:http://dx.doi.org/10.1080/21645515.2017.1342021
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares